SCHEMBL967202

SCHEMBL967202

Cc1cc2sc3c(c2nn1)CCN(CC(=O)N1CCN(C2CCC2)CC1)C3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.39
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 1/20 0.35
G6PD P11413 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
HSD17B10 Q99714 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
HRH3 Q9Y5N1 5/20 0.34
POLB P06746 1/20 0.33
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968650 0.83 PARP1 (0.39) PARP1ALDH1A1KDM4EHRH3
SCHEMBL968740 0.79 PARP1 (0.38) PARP1HTTNPSR1ALDH1A1KDM4E
SCHEMBL969018 0.78 PARP1 (0.40) PARP1HTTNPSR1ALDH1A1KDM4E
SCHEMBL969094 0.78 PARP1 (0.44) PARP1HTTNPSR1ALDH1A1KDM4E
SCHEMBL967364 0.78 PARP1 (0.52) PARP1HTTNPSR1ALDH1A1KDM4E
SCHEMBL12920055 0.77 PARP1 (0.41) PARP1HTTNPSR1ALDH1A1KDM4E
SCHEMBL969746 0.77 HRH3 (0.41) PARP1HRH3
SCHEMBL969816 0.77 PARP1 (0.39) PARP1HTTALDH1A1KDM4ELMNA
SCHEMBL970345 0.77 HRH3 (0.41) PARP1KMT2AL3MBTL1HRH3
SCHEMBL971049 0.76 HRH3 (0.40) PARP1HTTALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885HTT 661/4885NPSR1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.